

CLAIMS

1. A method of treatment of a human subject considered in need of maintaining or improving hemodynamic stability comprising administering to said subject a peptide comprising at least 50% amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G), valine (V), leucine (L), isoleucine (I), proline (P) and arginine (R).
5
2. A method of treatment of a human subject considered in need of reducing adverse vascular permeability comprising administering to said subject a peptide comprising at least 50% amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G), valine (V), leucine (L), isoleucine (I), proline (P) and arginine (R).
10
3. A method of treatment of a human subject considered in need of reducing adverse fluid retention comprising administering to said subject a peptide comprising at least 50% amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G), valine (V), leucine (L), isoleucine (I), proline (P) and arginine (R).
15
4. A method of treatment according to anyone of claims 1-3 wherein said peptide comprises at least 75% amino acids selected from said group of autophagy inhibiting amino acids.
20
5. A method of treatment according to anyone of claims 1-4 wherein said peptide consists of amino acids selected from said group of autophagy inhibiting amino acids.
6. A method of treatment according to anyone of claims 1-5 wherein said peptide comprises at least 50% amino acids selected from the group of autophagy inhibiting amino acids alanine (A), glutamine (Q), and leucine (L).
25
7. A method of treatment according to anyone of claims 1-6 wherein said peptide comprises at most 30% amino acids selected from the group of autophagy inhibiting amino acids glycine (G), valine (V), isoleucine (I), proline (P) and arginine (R).
30

8. A method of treatment according to anyone of claims 1-7 comprising administering to said subject at least two different peptides each comprising at least 50% amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G), valine (V), leucine (L), isoleucine (I), proline (P) and arginine (R).
9. A method according to anyone of claims 1-8 wherein said peptide or peptides vary in length from 4-30 amino acids.
10. A method of treatment according to anyone of claims 1-9 wherein said subject has been subjected to severe trauma such as surgery.
11. A method of treatment according to anyone of claims 1-9 wherein said subject has been subjected to cancer treatment such as treatment with an antineoplastic or immunomodulating agent.
12. A method of treatment according to anyone of claims 1-9 wherein said subject is considered to suffer from capillary leakage syndrome such as seen with an adverse drug reaction.
13. A method according to anyone of claims 1-12, the human subject having impaired kidney function.
14. A method according to anyone of claims 1-13, wherein the method comprises a reduced use of vasopressive agents.
15. A method according to anyone of claims 1-14, wherein the method comprises a reduced fluid intake.
16. A method according to anyone of claims 1-15 wherein the peptide comprises at least 50% amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G) and valine (V).
17. A method according to anyone of claims 1-15 wherein the peptide consists of amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G) and valine (V).
18. A method according to anyone of claims 1-17 wherein the peptide is a salt selected from the group of peptide-organic acid.
19. A peptide for use in treatment of a human subject considered in need of maintaining or improving hemodynamic stability said peptide comprising at least

- 50% amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G), valine (V), leucine (L), isoleucine (I), proline (P) and arginine (R).
- 5 20. A peptide for use in treatment of a human subject considered in need of reducing adverse vascular permeability said peptide comprising at least 50% amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G), valine (V), leucine (L), isoleucine (I), proline (P) and arginine (R).
- 10 21. A peptide for use in treatment of a human subject considered in need of reducing adverse fluid said peptide comprising at least 50% amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G), valine (V), leucine (L), isoleucine (I), proline (P) and arginine (R).
- 15 22. A peptide according to anyone of claims 19-21 wherein said subject has been subjected to severe trauma such as surgery.
23. A peptide according to anyone of claims 19-21 wherein said subject has been subjected to cancer treatment such as treatment with an antineoplastic or immunomodulating agent.
- 20 24. A peptide according to anyone of claims 19-21 wherein said subject is considered to suffer from capillary leakage syndrome such as seen with an adverse drug reaction.
- 25 25. A peptide according to anyone of claims 19-24, the human subject having impaired kidney function.
26. A peptide according to anyone of claims 19-25, wherein the use comprises a reduced use of vasopressive agents.
27. A peptide according to anyone of claims 19-26, wherein the use comprises a reduced fluid intake.
- 30 28. A peptide according to anyone of claims 19-27 wherein the peptide comprises at least 50% amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G) and valine (V).

29. A peptide according to claim 28 wherein the peptide consists of amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G) and valine (V).
30. A peptide according to claim 29 wherein the peptide is a salt selected from the group of peptide-acetate, peptide-tartrate or peptide-citrate.
31. A pharmaceutical formulation comprising a peptide according to anyone of claims 19-30.
32. A pharmaceutical formulation according to claim 31 wherein said peptide comprises at least 75% amino acids selected from said group of autophagy inhibiting amino acids.
33. A pharmaceutical formulation according to anyone of claims 31 or 32 wherein said peptide consists of 100% amino acids selected from said group of autophagy inhibiting amino acids.
34. A pharmaceutical formulation according to anyone of claims 31-33 wherein said peptide comprises at least 50% amino acids selected from the group of autophagy inhibiting amino acids alanine (A), glutamine (Q), and leucine (L).
35. A pharmaceutical formulation according to anyone of claims 31-34 wherein said peptide comprises at most 30% amino acids selected from the group of autophagy inhibiting amino acids glycine (G), valine (V), isoleucine (I), proline (P) and arginine (R).
36. A pharmaceutical formulation according to anyone of claims 31-35 comprising at least two different peptides each comprising at least 50% amino acids selected from the group of autophagy inhibiting amino acids alanine (in one letter code: A), glutamine (Q), glycine (G), valine (V), leucine (L), isoleucine (I), proline (P) and arginine (R).
37. A pharmaceutical formulation according to anyone of claims 31-36 wherein said peptide or peptides vary in length from 4-30 amino acids.
38. A pharmaceutical formulation to anyone of claims 31-37 comprising at least 0.85mol/L of said peptide or peptides.
39. A pharmaceutical formulation according to anyone of claims 31-38 and at least one pharmaceutically acceptable excipient.

40. A stock solution comprising a pharmaceutical formulation according to anyone of claims 31-39.
41. A formulation or solution according to anyone of claims 31-40 for use in a method of treatment of a human subject considered in need of maintaining or improving hemodynamic stability.
42. A formulation or solution according to anyone of claims 31-40 for use in a method of treatment of a human subject considered in need of reducing adverse vascular permeability.
43. A formulation or solution according to anyone of claims 31-40 for use in a method of treatment of a human subject considered in need of reducing adverse fluid retention.
44. A formulation or solution according to anyone of claims 31-40 for use in a method of treatment of a human subject suffering or considered suffering from Clarkson's disease (CLS).
45. A method of treatment of a human subject considered in need of maintaining or improving hemodynamic stability comprising administering to said subject a formulation or solution according to anyone of claims 31-40.
46. A method of treatment of a human subject considered in need of reducing adverse vascular permeability comprising administering to said subject a formulation or solution according to anyone of claims 31-40.
47. A method of treatment of a human subject considered in need of reducing adverse fluid retention comprising administering to said subject a formulation or solution according to anyone of claims 31-40.
48. A method of treatment of a human subject suffering or considered suffering from Clarkson's disease (CLS) comprising administering to said subject a formulation or solution according to anyone of claims 31-40.